Skip to content

Drug interactions

Oritavancin + Valproic acid

Severity: Minor

Oritavancin and Valproic acid: minor interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Oritavancin is a weak inhibitor of CYP2C19, which contributes only a minor share of valproate metabolism. A meaningful rise in valproate concentrations is therefore unlikely.

What this interaction means in plain words

Oritavancin and Valproic acid have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.

Oritavancin belongs to Anti Bacterial; Valproic acid belongs to Central Nervous System.

Evidence level: Low

Why it happens

Weak CYP2C19 inhibition by oritavancin affecting a minor valproate metabolic pathway.

What to do

No empiric dose change is needed. Monitor for valproate adverse effects or check a level if toxicity is suspected.

What to ask your pharmacist

  • Is there anything I should notice while taking both?
  • Do I need to tell my doctor at the next visit?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Oritavancin and Valproic acid, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Oritavancin with Valproic acid?

MediHelp rates the interaction as minor. Oritavancin and Valproic acid have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Oritavancin is a weak inhibitor of CYP2C19, which contributes only a minor share of valproate metabolism. A meaningful rise in valproate concentrations is therefore unlikely.

How serious is the interaction between Oritavancin and Valproic acid?

MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No empiric dose change is needed. Monitor for valproate adverse effects or check a level if toxicity is suspected.

What other medicines interact with Valproic acid?

MediHelp also lists interactions of Valproic acid with, for example, Ertapenem, Imipenem / cilastatin / relebactam, Imipenem / cilastatin. The full list is on the Valproic acid page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in